Resmetirom MGL-3196 is a drug that is currently in development for the treatment of various metabolic disorders, including hyperlipidemia and nonalcoholic steatohepatitis (NASH). This innovative drug is a selective thyroid hormone receptor-β (THR-β) agonist, which means that it activates the THR-β receptors in the liver to enhance lipid metabolism, reduce inflammation, and improve insulin sensitivity.
Chemical Name and Molecular Formula:
The chemical name for Resmetirom MGL-3196 is (2S,4R)-N-[4-cyano-3-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-2-[(methylsulfonyl)amino]-1-pyrrolidinecarboxamide. The molecular formula of the drug is C22H20F4N4O3S, and its molar mass is 520.48 g/mol.
The CAS number for Resmetirom MGL-3196 is 920509-32-6.
Top Ten Keywords and Synonyms:
Health Benefits of Resmetirom MGL-3196:
Resmetirom MGL-3196 has several potential health benefits, especially in the treatment of metabolic disorders such as hyperlipidemia and NASH. Clinical trials have shown that the drug has the potential to lower LDL (bad) cholesterol levels and triglycerides, increase HDL (good) cholesterol levels, decrease liver fat, and improve insulin sensitivity. Moreover, Resmetirom MGL-3196 is a selective THR-β agonist that works by targeting the liver and activating the THR-β receptors. This drug offers a promising solution to patients who struggle with these metabolic disorders, as current treatments are often ineffective.
Potential Effects of Resmetirom MGL-3196:
Resmetirom MGL-3196 has potential effects on lipid metabolism, inflammation reduction, and insulin sensitivity improvement. The drug activates the selective THR-β receptors in the liver to enhance the metabolism of lipids and decrease liver fat. In addition, Resmetirom MGL-3196 has an anti-inflammatory effect on the liver, which is essential in the treatment of NASH. The drug also increases insulin sensitivity, which can help prevent diabetes and other related metabolic disorders.
Resmetirom MGL-3196 works as a selective thyroid hormone receptor-β (THR-β) agonist, which activates the THR-β receptors in the liver. This activation leads to the enhancement of lipid metabolism, reduced inflammation, and improved insulin sensitivity. The selective activation of THR-β receptors in the liver is a novel mechanism of action that provides a targeted approach to treating metabolic disorders.